These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21516865)

  • 1. [The role of antiangiogenic agents in age related macular degeneration].
    Tomi A
    Oftalmologia; 2010; 54(4):63-72. PubMed ID: 21516865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
    Emerson MV; Lauer AK
    BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
    Nelson M
    Retina; 2010 Feb; 30(2):380; author reply 380-1. PubMed ID: 20142719
    [No Abstract]   [Full Text] [Related]  

  • 4. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Kaiser PK; ; Boyer DS; Garcia R; Hao Y; Hughes MS; Jabbour NM; Kaiser PK; Mieler W; Slakter JS; Samuel M; Tolentino MJ; Roth D; Sheidow T; Strong HA
    Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
    Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
    Retina; 2006; 26(9):988-93. PubMed ID: 17151484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
    Shah GK; Sang DN; Hughes MS
    Retina; 2009 Feb; 29(2):133-48. PubMed ID: 19202423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.
    Heier JS; Boyer DS; Ciulla TA; Ferrone PJ; Jumper JM; Gentile RC; Kotlovker D; Chung CY; Kim RY;
    Arch Ophthalmol; 2006 Nov; 124(11):1532-42. PubMed ID: 17101999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic therapy in neovascular age-related macular degeneration.
    Lin RC; Rosenfeld PJ
    Int Ophthalmol Clin; 2007; 47(1):117-37. PubMed ID: 17237677
    [No Abstract]   [Full Text] [Related]  

  • 10. Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration.
    Aggio FB; Melo GB; Höfling-Lima AL; Eid Farah M
    Acta Ophthalmol Scand; 2006 Dec; 84(6):831-3. PubMed ID: 17083553
    [No Abstract]   [Full Text] [Related]  

  • 11. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.
    Antoszyk AN; Tuomi L; Chung CY; Singh A;
    Am J Ophthalmol; 2008 May; 145(5):862-74. PubMed ID: 18321465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
    Brown DM; Kaiser PK; Michels M; Soubrane G; Heier JS; Kim RY; Sy JP; Schneider S;
    N Engl J Med; 2006 Oct; 355(14):1432-44. PubMed ID: 17021319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.
    Kaiser PK; Brown DM; Zhang K; Hudson HL; Holz FG; Shapiro H; Schneider S; Acharya NR
    Am J Ophthalmol; 2007 Dec; 144(6):850-857. PubMed ID: 17949673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration.
    Kaiser PK
    Curr Med Res Opin; 2007 Mar; 23(3):477-87. PubMed ID: 17355729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H; Abrams P
    Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular-targeted photodynamic therapy in the treatment of neovascular age-related macular degeneration: Clinical perspectives.
    Kawczyk-Krupka A; Bugaj AM; Potempa M; Wasilewska K; Latos W; Sieroń A
    Photodiagnosis Photodyn Ther; 2015 Jun; 12(2):161-75. PubMed ID: 25843911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological treatments for neovascular age-related macular degeneration: can mixed treatment comparison meta-analysis be useful?
    Virgili G; Novielli N; Menchini F; Murro V; Giacomelli G
    Curr Drug Targets; 2011 Feb; 12(2):212-20. PubMed ID: 20887240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
    Lazic R; Gabric N
    Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial.
    Bressler NM; Chang TS; Fine JT; Dolan CM; Ward J;
    Arch Ophthalmol; 2009 Jan; 127(1):13-21. PubMed ID: 19139332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.
    Bashshur ZF; Schakal A; Hamam RN; El Haibi CP; Jaafar RF; Noureddin BN
    Arch Ophthalmol; 2007 Oct; 125(10):1357-61. PubMed ID: 17923543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.